{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:12:52Z","timestamp":1786990372770,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019006","name":"State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Education","doi-asserted-by":"publisher","award":["CMEMR2021-B10"],"award-info":[{"award-number":["CMEMR2021-B10"]}],"id":[{"id":"10.13039\/501100019006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22175144"],"award-info":[{"award-number":["22175144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52073193"],"award-info":[{"award-number":["52073193"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2019YFS0531-6"],"award-info":[{"award-number":["2019YFS0531-6"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022YFS0636"],"award-info":[{"award-number":["2022YFS0636"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ijbiomac.2024.136831","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T12:33:13Z","timestamp":1729686793000},"page":"136831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"P2","title":["A nanoprodrug derived from branched poly (ethylene glycol) recognizes prostate-specific membrane antigen to precisely suppress prostate cancer progression"],"prefix":"10.1016","volume":"282","author":[{"given":"Shiwei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136831_bb0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.136831_bb0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.120.257238","article-title":"Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer","volume":"62","author":"Farolfi","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.136831_bb0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.euo.2022.03.004","article-title":"[(68)Ga]Ga-PSMA versus [(18)F]PSMA positron emission tomography\/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review of the literature","volume":"5","author":"Evangelista","year":"2022","journal-title":"Eur. Urol. Oncol."},{"issue":"14","key":"10.1016\/j.ijbiomac.2024.136831_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147431","article-title":"Enzalutamide enhances PSMA expression of PSMA-low prostate cancer","volume":"22","author":"Staniszewska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.136831_bb0025","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2022.05.010","article-title":"(18)F-PSMA-11 versus (68)Ga-PSMA-11 positron emission tomography\/computed tomography for staging and biochemical recurrence of prostate cancer: a prospective double-blind randomised cross-over trial","volume":"82","author":"De Man","year":"2022","journal-title":"Eur. Urol."},{"issue":"Suppl. 10","key":"10.1016\/j.ijbiomac.2024.136831_bb0030","first-page":"S19","article-title":"ProstaScint(R) scan: contemporary use in clinical practice","volume":"10","author":"Taneja","year":"2004","journal-title":"Rev. Urol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.136831_bb0035","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR Tcells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.ijbiomac.2024.136831_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122653","article-title":"Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications","volume":"9","author":"Aurilio","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.136831_bb0045","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","article-title":"KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer","volume":"81","author":"Gao","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.136831_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cells11050898","article-title":"Androgen receptor-mediated transcription in prostate cancer","volume":"11","author":"\u00d6zturan","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.136831_bb0055","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41388-020-01598-0","article-title":"Loss and revival of androgen receptor signaling in advanced prostate cancer","volume":"40","author":"Formaggio","year":"2021","journal-title":"Oncogene"},{"issue":"10336","key":"10.1016\/j.ijbiomac.2024.136831_bb0060","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.136831_bb0065","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.7150\/thno.73152","article-title":"Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","volume":"12","author":"Ma","year":"2022","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.136831_bb0070","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.ymthe.2021.04.029","article-title":"The roles of PD-1\/PD-L1 in the prognosis and immunotherapy of prostate cancer","volume":"29","author":"Xu","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0075","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.10.006","article-title":"Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel","volume":"468","author":"Shen","year":"2020","journal-title":"Cancer Lett."},{"issue":"20","key":"10.1016\/j.ijbiomac.2024.136831_bb0080","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","article-title":"Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer","volume":"70","author":"Zhu","year":"2010","journal-title":"Cancer Res."},{"issue":"2018","key":"10.1016\/j.ijbiomac.2024.136831_bb0085","first-page":"1","article-title":"A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: the RECARDO trial","volume":"90","author":"Bouman-Wammes","year":"1990","journal-title":"Eur. J. Cancer (Oxf. Engl.)"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136831_bb0090","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.136831_bb0095","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.136831_bb0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12032-016-0793-1","article-title":"Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer","volume":"33","author":"Schweizer","year":"2016","journal-title":"Med. Oncol. (Northwood, Lond. Engl.)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136831_bb0105","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12967-024-05347-9","article-title":"Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: from cancer therapy to regenerative medicine approaches","volume":"22","author":"Beheshtizadeh","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0110","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jconrel.2022.06.004","article-title":"Taxanes prodrug-based nanomedicines for cancer therapy","volume":"348","author":"Sun","year":"2022","journal-title":"J. Control. Release"},{"issue":"26","key":"10.1016\/j.ijbiomac.2024.136831_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202312169","article-title":"Nanomedicine tumor targeting","volume":"36","author":"Lammers","year":"2024","journal-title":"Adv. Mater. (Deerfield Beach Fla.)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136831_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1039\/D2CS00437B","article-title":"Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation","volume":"52","author":"Li","year":"2023","journal-title":"Chem. Soc. Rev."},{"issue":"52","key":"10.1016\/j.ijbiomac.2024.136831_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202101460","article-title":"Small-molecule prodrug nanoassemblies: an emerging nanoplatform for anticancer drug delivery","volume":"17","author":"Li","year":"2021","journal-title":"Small"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.136831_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16040473","article-title":"Evaluation of advanced nanomaterials for cancer diagnosis and treatment","volume":"16","author":"Ndlovu","year":"2024","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ijbiomac.2024.136831_bb0135","doi-asserted-by":"crossref","first-page":"14693","DOI":"10.1021\/acsnano.2c05341","article-title":"Hypoxia-activated PEGylated paclitaxel prodrug nanoparticles for potentiated chemotherapy","volume":"16","author":"Hao","year":"2022","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.136831_bb0140","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","article-title":"Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells","volume":"5","author":"Zhang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0145","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jconrel.2023.02.007","article-title":"Obesity and inflammation influence pharmacokinetic profiles of PEG-based nanoparticles","volume":"355","author":"Raith","year":"2023","journal-title":"J. Control. Release"},{"issue":"19","key":"10.1016\/j.ijbiomac.2024.136831_bb0150","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1039\/D3CC06098E","article-title":"Engineering poly(ethylene glycol) particles for targeted drug delivery","volume":"60","author":"Li","year":"2024","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jconrel.2020.04.039","article-title":"Application of star poly(ethylene glycol) derivatives in drug delivery and controlled release","volume":"323","author":"Zhao","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113372","article-title":"Poly ethylene glycol (PEG)-related controllable and sustainable antidiabetic drug delivery systems","volume":"217","author":"Fu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121415","article-title":"Branched PEG-modification: a new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy","volume":"283","author":"Liu","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114773","article-title":"Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments","volume":"196","author":"Sun","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.ijbiomac.2024.136831_bb0175","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1021\/acsnano.2c05379","article-title":"Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy","volume":"16","author":"Ding","year":"2022","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136831_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103849","article-title":"Bioresponsive drug delivery systems","volume":"29","author":"Alavi","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"24","key":"10.1016\/j.ijbiomac.2024.136831_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201901810","article-title":"Efficient intestinal digestion and on site tumor-bioactivation are the two important determinants for chylomicron-mediated lymph-targeting triglyceride-mimetic docetaxel oral prodrugs","volume":"6","author":"Tian","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202401744","article-title":"Responsive multi-arm PEG-modified cof nanocomposites: dynamic photothermal, pH\/ROS dual-responsive, targeted carriers for rheumatoid arthritis treatment","author":"Ge","year":"2024","journal-title":"Adv. Healthc. Mater."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.136831_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202306230","article-title":"Enzyme-responsive branched glycopolymer-based nanoassembly for co-delivery of paclitaxel and akt inhibitor toward synergistic therapy of gastric cancer","volume":"11","author":"Song","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0200","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2147\/IJN.S431599","article-title":"Preparation, characterization, and anti-lung cancer activity of tetrandrine-loaded stealth liposomes","volume":"19","author":"Fang","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0205","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.2147\/IJN.S471734","article-title":"Research progress of disulfide bond based tumor microenvironment targeted drug delivery system","volume":"19","author":"Ma","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.136831_bb0210","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136831_bb0215","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136831_bb0220","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41416-020-01149-0","article-title":"Mutational drivers of cancer cell migration and invasion","volume":"124","author":"Novikov","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136831_bb0225","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41467-021-21860-7","article-title":"A noncanonical AR addiction drives enzalutamide resistance in prostate cancer","volume":"12","author":"He","year":"2021","journal-title":"Nat. Commun."},{"issue":"43","key":"10.1016\/j.ijbiomac.2024.136831_bb0230","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2205350119","article-title":"A COP1-GATA2 axis suppresses AR signaling and prostate cancer","volume":"119","author":"Shen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.136831_bb0235","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles for cancer therapy","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2024.136831_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117125","article-title":"PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer","volume":"177","author":"Adekiya","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.136831_bb0245","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1021\/acs.nanolett.3c00704","article-title":"Rational engineering docetaxel prodrug nanoassemblies: response modules guiding efficacy enhancement and toxicity reduction","volume":"23","author":"Wang","year":"2023","journal-title":"Nano Lett."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024076402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024076402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:13:34Z","timestamp":1778627614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024076402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":49,"alternative-id":["S0141813024076402"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.136831","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A nanoprodrug derived from branched poly (ethylene glycol) recognizes prostate-specific membrane antigen to precisely suppress prostate cancer progression","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.136831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"136831"}}